A display area 60 of a display unit of a mass spectrometer shows a result of tuning. The display area 60 includes: a tuning-item displaying section 62 configured to display all tuning items and a result of whether each tuning item has been tuned; and an analyzable-condition displaying section 63 configured to display a condition under which an analysis is possible based on the result. The tuning items may be displayed respectively and individually. Alternatively, the tuning items may be displayed in a grouped manner with a plurality of tuning items in a group. Consequently, a user knows, at a glance, whether the tuning necessary for an analysis that the user intends to perform has been performed. If a necessary tuning item has not been tuned, the user immediately starts to tune (only) the tuning item. Further, a user immediately knows in a current state of tuning whether the analysis that the user intends to perform is possible. Therefore, when the analysis is possible, the user can start the analysis. When the analysis is impossible, the user can tune only the tuning item that has not been tuned and is displayed on the tuning-item displaying section 62.

The automatic analysis device includes an evaporative concentration unit configured to perform a concentration process of evaporating an extract solution obtained by extracting a component to be analyzed in a sample to concentrate the component to be analyzed; an analysis unit configured to analyze the component to be analyzed of the sample; and a control unit configured to control operations of the analysis unit and the evaporative concentration unit. The control unit determines whether to perform an evaporative concentration process on a component to be analyzed in the sample, and controls the evaporative concentration unit to concentrate a component to be analyzed in a sample which is determined to be subjected to an evaporative concentration process. The sample to be subjected to the evaporative concentration process is stored, and the control unit selects whether to perform the evaporative concentration on each sample or not based on stored content.

The present invention relates to a biomarker for diagnosing pancreatic cancer and use thereof. The marker according to the present application can significantly predict or determine, through a 14-multimarker panel, the onset likelihood, early diagnosis, and severity of pancreatic cancer or precancerous lesions of pancreatic cancer, and can be used in research on the tumorigenesis of pancreatic cancer.

An exemplary chromatographic alignment system accesses a target file including data representative of a plurality of chromatographic features detected from a first sample and a reference file including data representative of a plurality of chromatographic features detected from a second sample. The system identifies, based on the target and reference files, a distinct retention time offset value for each chromatographic feature included in a first subset of the plurality of chromatographic features detected from the first sample. The system determines, based on the identified distinct retention time offset values for the chromatographic features included in the first subset and on a machine learning model, a distinct predicted retention time offset value for each chromatographic feature included in a second subset of the plurality of chromatographic features detected from the first sample. The system assigns the distinct predicted retention time offset value for each chromatographic feature included in the second subset.

The present disclosure relates to a method of characterizing proteins in a sample. The method includes: removing non-ionic surfactant from the sample via denaturing size-exclusion chromatography to form a denatured sample; eluting the denatured sample via liquid chromatography to collect fractions of the sample, wherein the fractions of the sample include a protein fraction; lyophilizing the protein fraction to increase protein concentration; reconstituting the lyophilized protein fraction with a buffer comprising a surfactant to denature the protein; digesting the denatured protein fraction with an enzyme; and analyzing the digested protein fraction.

The present disclosure relates to CO.sub.2-based chromatography for the efficient and precise separation of Vitamin D metabolites.

The present application relates to methods for determining the concentration of one or more hormones in a sample by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

A portable apparatus to sample and analyze volatile organic compounds in breath air, includes: a box internally divided in two internal sections, each housing a sample collecting tube or filter in turn containing a stationary phase suitable for retaining determined analytes, as drugs and/or respective metabolites, having specific chemical physical properties, contained in breath air; a pre-accumulation chamber for receiving breath air from the outside through a breath entrance connection and for feeding the received breath air to the sample collecting filters housed in the two sections, with these two sample collecting filters being connected in parallel to the chamber; and a tool application kit for removing the two sample collecting filters from the respective sections in the box of the apparatus, in a way that avoids any contamination thereof, and for extracting the analytes that are retained by the stationary phase on the same two sample collecting filters.

The present invention provides a rapid, sensitive method for forensic drug testing in a post-mortem subject using oral fluid collected from the post-mortem subject. The method comprises collecting a sample of oral fluid from a post-mortem subject, analyzing the oral fluid sample qualitatively to detect the presence of one or more non-naturally occurring drugs, analyzing the oral fluid sample quantitatively to determine concentration of the one or more non-naturally occurring drugs in the post-mortem subject, and identifying the one or more non-naturally occurring drugs in the post-mortem subject. The detection and quantification in oral fluid is more sensitive and faster than detection and quantification of the non-naturally occurring drugs in blood, urine, bile, and liver tissue collected from the same post-mortem subject. Further, the qualitative and quantitative results are obtained in as little as three hours.

Systems and methods are described to provide speciation of silicon species present in a remote sample for analysis. A method embodiment includes, but is not limited to, receiving a fluid sample containing inorganic silicon in the presence of bound silicon from a remote sampling system via a fluid transfer line; transferring the fluid sample to an inline chromatographic separation system; separating the inorganic silicon from the bound silicon via the inline chromatographic separation system; transferring the separated inorganic silicon and bound silicon to a silicon detector in fluid communication with the inline chromatographic separation system; and determining an amount of one or more of the inorganic silicon or the bound silicon in the fluid sample via the silicon detector.